Portal de Periódicos da CAPES

Long term effect of apraclonidine.

1995; BMJ; Volume: 79; Issue: 12 Linguagem: Inglês

10.1136/bjo.79.12.1098

1468-2079

Silvana V. Araujo, J. Brent Bond, R P Wilson, Marlene R. Moster, Courtland M. Schmidt, G. L. Spaeth,

Pituitary Gland Disorders and Treatments

To evaluate the effect of the chronic use of apraclonidine 0.5% on the intraocular pressure (IOP) of patients with glaucoma; also, to study the side effect profile of this drug when used chronically.All patients who had uncontrolled IOP, who were either already on glaucoma medications, or who were intolerant of other glaucoma medications were enrolled. A total of 185 patients were started on apraclonidine 0.5% two to three times a day in one eye.Follow up extended to 35 weeks. The mean difference in IOP between treated and control eyes was 2.1 (SD 5.0) mm Hg. A similar IOP lowering effect was obtained comparing IOP difference from baseline in the treated eye only.By the end of the follow up period, 46% of patients were still on the medication. The drug was stopped in 23% of patients because of side effects and in 31% of patients because of failure to lower IOP significantly.